BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24093908)

  • 1. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
    Avallone A; Di Gennaro E; Silvestro L; Iaffaioli VR; Budillon A
    Expert Opin Drug Saf; 2014 Jan; 13(1):113-29. PubMed ID: 24093908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
    Gunasekara NS; Faulds D
    Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
    Nutting C; Folkes A
    Clin Oncol (R Coll Radiol); 1999; 11(1):66. PubMed ID: 10194593
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug resistance in colon cancer.
    Gorlick R; Bertino JR
    Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs in therapy of colorectal cancer: preclinical studies.
    Rustum YM; Cao S
    Semin Oncol; 1999 Dec; 26(6):612-20. PubMed ID: 10606254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
    Ford HE; Mitchell F; Cunningham D; Farrugia DC; Hill ME; Rees C; Calvert AH; Judson IR; Jackman AL
    Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Raltitrexed in colorectal cancer].
    Comandone A; Oliva C; Dal Canton O; Boglione A; Bergnolo P
    Tumori; 2001; 87(1 Suppl 1):S53-4. PubMed ID: 11300026
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
    Sato A; Kurihara M; Horikoshi N; Aiba K; Kikkawa N; Shirouzu K; Mitachi Y; Sakata Y; Wakui A
    Anticancer Drugs; 1999 Sep; 10(8):741-8. PubMed ID: 10573207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raltitrexed: optimism and reality.
    Wilson KS; Malfair Taylor SC
    Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1447-54. PubMed ID: 19863453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials referral resource. Clinical trials with tomudex.
    Sorensen JM; Cheson BD; Phillips PH
    Oncology (Williston Park); 1996 Jul; 10(7):1041-2. PubMed ID: 8837120
    [No Abstract]   [Full Text] [Related]  

  • 11. Raltitrexed, a new drug for advanced colorectal cancer.
    Mead GM
    Lancet; 1996 Jun; 347(9015):1568-9. PubMed ID: 8667859
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and tolerability of a new inhibitor of thymidylate synthase: 'Tomudex' (raltitrexed).
    Cunningham D
    Tumori; 1997; 83(1 Suppl):S70-1. PubMed ID: 9154074
    [No Abstract]   [Full Text] [Related]  

  • 13. Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil.
    Kempin S; Gutierrez J; Wilson E; Lowery C; Diasio R
    Cancer Invest; 2002; 20(7-8):992-5. PubMed ID: 12449732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.
    Cunningham D; Zalcberg J; Smith I; Gore M; Pazdur R; Burris H; Meropol NJ; Kennealey G; Seymour L
    Ann Oncol; 1996 Feb; 7(2):179-82. PubMed ID: 8777175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
    Köhne CH; Thuss-Patience P; Friedrich M; Daniel PT; Kretzschmar A; Benter T; Bauer B; Dietz R; Dörken B
    Br J Cancer; 1998 Mar; 77(6):973-7. PubMed ID: 9528843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and preclinical pharmacokinetics of raltitrexed.
    Clarke SJ; Beale PJ; Rivory LP
    Clin Pharmacokinet; 2000 Dec; 39(6):429-43. PubMed ID: 11192475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer].
    Jerusalem G; Bours V; Fillet G
    Rev Med Liege; 1998 Jun; 53(6):318-21. PubMed ID: 9713208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mature results from three large controlled studies with raltitrexed ('Tomudex').
    Cunningham D
    Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phase I study of raltitrexed (ZD-1694)].
    Horikoshi N; Aiba K; Fukuoka M; Akazawa S; Sakata Y; Furuse K; Kanamaru R; Kudoh S; Konishi T; Kurihara M; Niitani H; Furue H; Tsukagoshi S; Taguchi T; Yoshida S; Ota K; Kotake T; Wakui A
    Gan To Kagaku Ryoho; 1998 Nov; 25(13):2075-84. PubMed ID: 9838910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Absence of cross resistance between an irinotecan plus cisplatin combination and raltitrexed (ZD1694) in two patients with advanced colorectal cancer].
    Sato A; Kurihara M; Matsukawa M; Yamazaki T; Shimada K; Endo W; Yamazaki T; Nakamachi M
    Gan To Kagaku Ryoho; 2000 Apr; 27(4):617-21. PubMed ID: 10791007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.